<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614183</url>
  </required_header>
  <id_info>
    <org_study_id>15767</org_study_id>
    <secondary_id>I5Q-MC-CGAG</secondary_id>
    <nct_id>NCT02614183</nct_id>
  </id_info>
  <brief_title>Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study</brief_title>
  <acronym>EVOLVE-1</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of the study drug known as
      galcanezumab in participants with episodic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">August 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Rating</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in Headache Hours</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</measure>
    <time_frame>Month 1 through Month 6</time_frame>
    <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</measure>
    <time_frame>Month 6</time_frame>
    <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Month 6</time_frame>
    <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">862</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given by SC injection once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given by SC injection once a month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab 120mg</arm_group_label>
    <arm_group_label>Galcanezumab 240mg</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of episodic migraine as defined by International Headache Society
             (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1
             or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior
             to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 Migraine
             Headache Days (MHD).

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to Galcanezumab or another CGRP antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to Galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Territory Neurology &amp; Research Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Grove Family Practice</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute, Newport Beach</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tooraj Joseph Raoof M.D., Inc.</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fullerton Neurology and Headache Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute, Newport Beach</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute, Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mile High Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Research, LLC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Inst of Florida-Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accord Clinical Research, LLC</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Reserach . LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research LLC</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network - Blue Island</name>
      <address>
        <city>Blue Island</city>
        <state>Illinois</state>
        <zip>60406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana, LLC</name>
      <address>
        <city>Elwood</city>
        <state>Indiana</state>
        <zip>46036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Inc</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Clinical Trial Services, Inc.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research, Inc</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otri-Med Corporation</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-Marc Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSite Research Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head, Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinVest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthy Perspectives Innovative Mental Health Services, PL</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fieve Clincial Services</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Neurological Associates, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research Inc</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Ohio at Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultant</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network Inc</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 Medical Park</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists Inc</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Brampton</city>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Mississauga</city>
        <zip>L4Y 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Ruddy Guerra</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NuFrontiers Clinical Research LLC</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00923</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group PSC</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurologia Dra. Ivonne Fraga</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro GI Wellness Center</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN-us/studies/headache/cgag</url>
    <description>Click here for more information about this study: Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <results_first_submitted>October 8, 2018</results_first_submitted>
  <results_first_submitted_qc>November 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <disposition_first_submitted>March 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 19, 2018</disposition_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02614183/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02614183/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants (pts) received placebo by subcutaneous injection once a month for 6 months. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P2">
          <title>Galcanezumab 120mg</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P3">
          <title>Galcanezumab 240mg</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="434"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="206">One pt randomized to placebo received galcanezumab 120mg due to dosing error moved to this group.</participants>
                <participants group_id="P3" count="220">Eight pts discontinued after loading dose of 240mg galcanezumab in 120mg group moved to this group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post Treatment Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="372">Participants who discontinued double blind phase had an option to enter post-treatment phase.</participants>
                <participants group_id="P2" count="185">Participants who discontinued double blind phase had an option to enter post-treatment phase.</participants>
                <participants group_id="P3" count="183">Participants who discontinued double blind phase had an option to enter post-treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="372"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="185">Two participants who received only 240mg loading dose prior to discontinuation moved to this group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B2">
          <title>Galcanezumab 120mg</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B3">
          <title>Galcanezumab 240mg</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="212"/>
            <count group_id="B4" value="858"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.33" spread="11.40"/>
                    <measurement group_id="B2" value="40.93" spread="11.87"/>
                    <measurement group_id="B3" value="39.07" spread="11.52"/>
                    <measurement group_id="B4" value="40.67" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="718"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="710"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="690"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="187"/>
                    <measurement group_id="B4" value="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine Headache Days (MHD) per month</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.</description>
          <units>Days per Month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.08" spread="2.97"/>
                    <measurement group_id="B2" value="9.21" spread="3.05"/>
                    <measurement group_id="B3" value="9.14" spread="2.91"/>
                    <measurement group_id="B4" value="9.13" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.24"/>
                    <measurement group_id="O2" value="-4.73" spread="0.29"/>
                    <measurement group_id="O3" value="-4.57" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.31</ci_lower_limit>
            <ci_upper_limit>-1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="1.7"/>
                    <measurement group_id="O2" value="62.3" spread="2.4"/>
                    <measurement group_id="O3" value="60.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="1.4"/>
                    <measurement group_id="O2" value="38.8" spread="2.4"/>
                    <measurement group_id="O3" value="38.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.8"/>
                    <measurement group_id="O2" value="15.6" spread="1.6"/>
                    <measurement group_id="O3" value="14.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥50%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥50%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.94</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥75%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥75%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.01</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline = 100%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline = 100%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>3.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain</title>
        <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain</title>
          <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.69" spread="1.07"/>
                    <measurement group_id="O2" value="32.43" spread="1.31"/>
                    <measurement group_id="O3" value="32.09" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.20</ci_lower_limit>
            <ci_upper_limit>10.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.83</ci_lower_limit>
            <ci_upper_limit>9.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</title>
        <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="0.21"/>
                    <measurement group_id="O2" value="-3.96" spread="0.25"/>
                    <measurement group_id="O3" value="-3.76" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>-1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>-1.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Rating</title>
        <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Rating</title>
          <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.08"/>
                    <measurement group_id="O2" value="-1.59" spread="0.10"/>
                    <measurement group_id="O3" value="-1.55" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in Headache Hours</title>
        <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in Headache Hours</title>
          <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>Hours per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.67" spread="2.24"/>
                    <measurement group_id="O2" value="-29.65" spread="2.70"/>
                    <measurement group_id="O3" value="-29.31" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.99</ci_lower_limit>
            <ci_upper_limit>-8.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.68</ci_lower_limit>
            <ci_upper_limit>-8.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
        <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
          <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.87" spread="1.37"/>
                    <measurement group_id="O2" value="-21.16" spread="1.65"/>
                    <measurement group_id="O3" value="-20.06" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.45</ci_lower_limit>
            <ci_upper_limit>-3.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.39</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</title>
        <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
        <time_frame>Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had least one non-missing test result for ADA for each of the baseline period and the post-baseline period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</title>
          <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
          <population>All randomized participants who received at least one dose of study drug and had least one non-missing test result for ADA for each of the baseline period and the post-baseline period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TE ADA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66"/>
                    <measurement group_id="O2" value="3.47"/>
                    <measurement group_id="O3" value="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing Antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42"/>
                    <measurement group_id="O2" value="3.47"/>
                    <measurement group_id="O3" value="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TE ADA Positive.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.160</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TE ADA Positive.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.020</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Neutralizing Antibodies.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.131</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Neutralizing Antibodies.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.009</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</title>
        <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</title>
          <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
          <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.</population>
          <units>Nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15400" spread="8340"/>
                    <measurement group_id="O2" value="29500" spread="12300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
        <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who had received at least one dose of study drug and had measurable plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
          <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
          <population>All randomized participants who had received at least one dose of study drug and had measurable plasma concentrations.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.888" spread="1.89"/>
                    <measurement group_id="O2" value="4.25" spread="1.79"/>
                    <measurement group_id="O3" value="5.13" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 10 Months</time_frame>
      <desc>All-Cause Mortality:All participants (pts) who received atleast 1 dose of study drug.
SAE/AE:Eight pts discontinued after receiving loading dose (LD) of 240mg galcanezumab (GAL) in 120mg group (gp) moved to 240mg treatment gp. One pt randomized to placebo received GAL 120mg due to dosing error moved to 120mg treatment gp. Two pts who received only 240mg LD prior to discontinuation moved to 240mg post-treatment gp. There are gender specific adverse events only occurring in male or female pts.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Treatment Phase</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Galcanezumab 120mg - Treatment Phase</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
        </group>
        <group group_id="E3">
          <title>Galcanezumab 240mg - Treatment Phase</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Post-Treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E5">
          <title>Galcanezumab 120mg - Post-Treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E6">
          <title>Galcanezumab 240mg - Post-Treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incarcerated incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tubular breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with mixed anxiety and depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="372"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="365" subjects_affected="75" subjects_at_risk="432"/>
                <counts group_id="E2" events="158" subjects_affected="33" subjects_at_risk="206"/>
                <counts group_id="E3" events="212" subjects_affected="45" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E3" events="20" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="432"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="372"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="432"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="372"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="432"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="206"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

